98%
921
2 minutes
20
Background: Left ventricular assist devices (LVADs) are increasingly used in the management of advanced heart failure. The majority of these patients have pre-existing implantable cardioverter defibrillators (ICDs). The proximity between the LVAD inflow cannula and right ventricular (RV) defibrillation lead raises the potential for disruption of ICD function.
Methods: This is a retrospective analysis of 95 patients with ICDs at a single tertiary care center who underwent LVAD implantation and who met inclusion criteria. The primary outcome was changes in the pre-operative and post-operative transvenous ICD RV lead parameters. These changes were stratified by the age of the RV lead and analyzed via a paired t-test. The secondary outcome was disruption to the ICD requiring an intervention.
Results: LVAD implantation was associated with significant decreases in sensed amplitude (p < 0.01) and high voltage impedance (p < 0.01) and an increase in capture threshold (p = 0.017). When stratified by age of the RV lead, patients with leads older than two years had similar trends in all parameters. However, RV leads that were two years old or younger only showed a significant change in high voltage impedance (p < 0.01). Mechanical disruption of the ICD related to the surgery was infrequent but significant.
Conclusion: Because LVAD implantation is capable of impacting ICD function and causing mechanical disruption, close monitoring should be paid to the ICD in the peri-operative period including obtaining a full interrogation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362136 | PMC |
http://dx.doi.org/10.1016/j.jhlto.2025.100350 | DOI Listing |
ACS Nano
September 2025
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Although traditional immunogenic cell death (ICD) inducers generate vaccines (ISV) to potentiate antiprogrammed cell death ligand 1 (anti-PDL1) antibodies therapy, their efficacy remains limited. This limitation may be attributed to the physical barrier created by extracellular matrix (ECM) and immunosuppressive metabolic barrier mediated by adenosine. Here, we report an oncolytic polymer (OP), a well-designed ε-polylysine derivative with ICD-inducing capacity, which can simultaneously facilitate the release of endogenous ECM-degrading enzyme, Cathepsin B.
View Article and Find Full Text PDFMater Today Bio
October 2025
Department of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Jinan, 250021, Shandong, China.
Adenoid cystic carcinoma (ACC) is a lethal salivary gland malignant neoplasm. Lung metastasis is the primary cause of mortality in ACC patients while there is no effective treatment available at present. In this study, a precise and biomimetic nanoplatform, CG/MC/U-M, is designed to combine cuproptosis, gas therapy and immunotherapy against metastatic adenoid cystic carcinoma.
View Article and Find Full Text PDFBiomater Sci
September 2025
School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Cancer immunotherapy has transformed oncological treatment paradigms, yet tumor resistance and immune evasion continue to limit therapeutic efficacy. Mitochondria-targeting organic sensitizers (MTOSs) represent an emerging class of therapeutic agents that exploit mitochondrial dysfunction as a convergent node for tumor elimination and immune activation. As central regulators of cellular metabolism, apoptotic signaling, and immune cell function, mitochondria serve as critical determinants of tumor progression and the immunological landscape within the tumor microenvironment (TME).
View Article and Find Full Text PDFNanomicro Lett
September 2025
School of Preclinical Medicine, Chengdu University, Chengdu, 610106, People's Republic of China.
Emerging ferroptosis-immunotherapy strategies, integrating functionalized nanoplatforms with ferroptosis-inducing agents and immunomodulatory therapeutics, demonstrate significant potential in managing primary, recurrent, and metastatic malignancies. Mechanistically, ferroptosis induction not only directly eliminates tumor cells but also promotes immunogenic cell death (ICD), eliciting damage-associated molecular patterns (DAMPs) release to activate partial antitumor immunity. However, standalone ferroptosis therapy fails to initiate robust systemic antitumor immune responses due to inherent limitations: low tumor immunogenicity, immunosuppressive microenvironment constraints, and tumor microenvironment (TME)-associated physiological barriers (e.
View Article and Find Full Text PDFInt Ophthalmol
September 2025
Ophthalmology Department, Ulm University Hospital, Ulm, Germany.
Purpose: This study investigated how the COVID-19 pandemic coincided with changes in incidence, seasonality, and surgical management of rhegmatogenous retinal detachment (RRD) and tractional retinal detachment (TRD) in Germany.
Methods: We performed an observational, retrospective analysis using data from the Diagnosis-Related Group database, covering 116,386 retinal detachment admissions between January 2019 and December 2022. RRD (ICD-10 H33.